Antifungal Agents

Correct Answer

B — Voriconazole

Rationale

Voriconazole is classified as the established first-line agent for invasive aspergillosis, supported by the landmark 2002 randomized trial demonstrating superior survival and response rates compared to amphotericin B deoxycholate. Isavuconazole is an alternative first-line agent following its non-inferiority demonstration in the SECURE trial. Fluconazole has no activity against Aspergillus species and cannot be used for this indication. Caspofungin is an echinocandin that is only fungistatic against Aspergillus and is not first-line as monotherapy for invasive aspergillosis. Nystatin is a topical polyene with no role in the treatment of invasive mold infections.

Correct Answer

D — Fluconazole

Rationale

Fluconazole is classified as the drug of choice for both consolidation and maintenance therapy in cryptococcal meningitis following amphotericin B-based induction. Consolidation consists of fluconazole 400 mg daily for eight weeks after induction. Maintenance therapy uses fluconazole 200 mg daily until the CD4 count exceeds 200 cells per microliter on antiretroviral therapy for at least six months. Fluconazole's suitability for this role depends on its excellent central nervous system penetration — cerebrospinal fluid concentrations reach 60 to 80 percent of plasma — and its reliable oral bioavailability. Voriconazole and itraconazole are not classified in this consolidation/maintenance role; itraconazole has poor central nervous system penetration. Caspofungin lacks Cryptococcus coverage.

Correct Answer

A — Liposomal amphotericin B

Rationale

Liposomal amphotericin B at five mg/kg per day is classified as the preferred primary antifungal for mucormycosis, initiated as early as possible — even before histologic confirmation when clinical suspicion is high. After clinical stabilization, step-down to oral posaconazole or isavuconazole has become standard practice. Voriconazole has no meaningful activity against the Mucorales and is not used for mucormycosis; patients receiving voriconazole prophylaxis have developed breakthrough mucormycosis as a recognized consequence. Fluconazole has no mold activity of any kind. Micafungin and other echinocandins lack activity against the Mucorales.

Correct Answer

C — Itraconazole

Rationale

Itraconazole is classified as the drug of choice for mild-to-moderate pulmonary histoplasmosis. It is dosed at 200 mg three times daily for three days as a loading regimen, then 200 mg twice daily for six to twelve weeks for mild-to-moderate disease. For moderately severe to severe disease and progressive disseminated histoplasmosis in immunocompromised patients, liposomal amphotericin B induction is required followed by itraconazole step-down therapy for at least twelve months. Voriconazole does not have established efficacy for histoplasmosis and is not recommended. Fluconazole has lower efficacy than itraconazole for histoplasmosis and is not first-line. Caspofungin is an echinocandin with no activity against Histoplasma capsulatum.

Correct Answer

B — Fluconazole

Rationale

Fluconazole is classified as the drug of choice for most non-life-threatening forms of coccidioidomycosis, including pulmonary disease requiring treatment and, most distinctively, coccidioidal meningitis. Coccidioidal meningitis requires lifelong fluconazole suppression at 400 mg daily because it cannot be cured with currently available antifungal agents. Fluconazole's selection for this role reflects its excellent central nervous system penetration — cerebrospinal fluid concentrations reach 60 to 80 percent of plasma — which is essential for treating meningeal infection. Itraconazole is preferred for bone and joint coccidioidomycosis. Voriconazole does not have an established role in coccidioidomycosis. Caspofungin has no activity against the dimorphic fungus Coccidioides.

Correct Answer

D — Voriconazole

Rationale

Voriconazole has no clinically meaningful activity against the Mucorales — the order of molds responsible for mucormycosis, including Rhizopus, Mucor, and Lichtheimia species. Patients receiving voriconazole for prophylaxis or aspergillosis treatment have developed breakthrough mucormycosis because voriconazole provides no coverage for these organisms. When mucormycosis is suspected in a patient already receiving voriconazole, the antifungal must be switched immediately to liposomal amphotericin B without waiting for mycologic confirmation. Posaconazole is the only oral azole with meaningful Mucorales activity and is approved for mucormycosis. Isavuconazole also has Mucorales coverage and is approved for mucormycosis. Liposomal amphotericin B is the preferred primary treatment for mucormycosis.

Correct Answer

C — Removal of the central venous catheter as soon as possible; treatment for 14 days from the first negative blood culture in uncomplicated cases

Rationale

Two management steps are essential in candidemia beyond antifungal therapy. First, the central venous catheter should be removed as soon as clinically feasible; catheter removal improves outcomes and reduces the time to blood culture clearance. Second, treatment duration for uncomplicated candidemia is 14 days from the first documented negative blood culture in a patient with no deep-seated infection and a functioning immune response. Repeat blood cultures are drawn daily until negative to establish this start date. Ophthalmologic evaluation — dilated funduscopic examination — is also recommended for all patients with candidemia because Candida endophthalmitis occurs in five to ten percent of cases regardless of visual symptoms. Galactomannan is a marker for Aspergillus, not Candida. Granulocyte infusions are not standard candidemia management.

Correct Answer

A — A cell wall polysaccharide antigen shed by Aspergillus hyphae during active growth; sensitivity approximately 70 to 80 percent in neutropenic patients and hematopoietic stem cell transplant recipients

Rationale

Galactomannan is a beta-glucan-containing cell wall polysaccharide antigen shed by Aspergillus hyphae into the bloodstream during active invasion. Serum galactomannan testing has validated sensitivity of approximately 70 to 80 percent in neutropenic patients and hematopoietic stem cell transplant recipients, with high specificity in these populations. Its diagnostic utility is reduced in solid organ transplant recipients and patients receiving antifungal prophylaxis. Beta-d-glucan is a different and broader pan-fungal marker that detects cell wall components from Aspergillus, Candida, and other fungi but lacks species specificity. Galactomannan is an antigen shed by the fungus — not an antibody produced by the host — and it is not universally detectable within 24 hours. The halo sign on high-resolution chest computed tomography — a nodule surrounded by ground-glass opacity representing hemorrhagic infarction — is a complementary radiologic finding characteristic of early invasive pulmonary aspergillosis.

Correct Answer

D — Elevated cerebrospinal fluid opening pressure is present in the majority of patients with cryptococcal meningitis, correlates with mortality, and requires management through serial therapeutic lumbar punctures independent of antifungal therapy

Rationale

Elevated cerebrospinal fluid opening pressure — above 25 cm H₂O — is present in the majority of patients with cryptococcal meningitis and is one of the strongest predictors of early mortality. The elevated pressure results from impaired cerebrospinal fluid resorption rather than from a mass lesion, and it does not resolve simply with antifungal treatment. Serial therapeutic lumbar punctures to reduce cerebrospinal fluid pressure are a life-saving intervention independent of antifungal therapy — they are performed until the opening pressure normalizes, typically requiring daily or every-other-day procedures initially. Elevated opening pressure in acute cryptococcal meningitis is not primarily caused by immune reconstitution inflammatory syndrome, which is a complication of antiretroviral therapy initiation that typically appears weeks later. Emergency shunting is reserved for refractory cases not responding to serial lumbar punctures.

Correct Answer

B — Antiretroviral therapy should be deferred two to four weeks after antifungal induction begins, because starting within the first two weeks dramatically worsens outcomes through immune reconstitution inflammatory syndrome

Rationale

Current guidelines recommend deferring antiretroviral therapy initiation for two to four weeks after starting antifungal induction for cryptococcal meningitis. Starting antiretroviral therapy within the first two weeks dramatically worsens outcomes — primarily through immune reconstitution inflammatory syndrome (IRIS), in which rapid recovery of Cryptococcus-specific immunity generates an exuberant inflammatory response in the central nervous system that can produce cerebral edema, herniation, and death. While antiretroviral therapy is essential and must ultimately be initiated — cryptococcal meningitis is an AIDS-defining illness — the timing must allow sufficient reduction in fungal burden during induction before immune recovery is triggered. Deferring beyond four weeks also carries risk from continued severe immunosuppression, so the two-to-four-week window represents the balance between these competing concerns. Drug interactions between antiretrovirals and antifungals are managed by appropriate agent selection, not by permanent deferral of antiretroviral therapy.

Correct Answer

C — Liposomal amphotericin B antifungal therapy; urgent surgical debridement of infected and necrotic tissue; reversal of predisposing conditions such as diabetic ketoacidosis, high-dose corticosteroids, and deferoxamine

Rationale

Mucormycosis requires three simultaneous interventions. First, liposomal amphotericin B at five mg/kg per day — initiated immediately, even before histologic confirmation when clinical suspicion is high. Second, urgent surgical debridement of infected and necrotic tissue, which is essential rather than optional; angioinvasion by Mucorales hyphae produces thrombosis and tissue necrosis that limits antifungal drug penetration, making surgery a required component of source control. Delay in surgery worsens outcomes, and repeated debridements are often necessary. Third, reversal of predisposing conditions: control of diabetic ketoacidosis, reduction of corticosteroid doses when possible, and discontinuation of deferoxamine — a drug that provides iron to Mucorales organisms and dramatically increases infection risk. Voriconazole has no Mucorales activity and must never be used. Corticosteroids worsen mucormycosis. Echinocandins lack Mucorales activity. Deferoxamine worsens rather than helps mucormycosis.

Correct Answer

A — Mild-to-moderate: itraconazole for six to twelve weeks; moderately severe to severe and disseminated in immunocompromised patients: liposomal amphotericin B induction for one to two weeks followed by itraconazole for at least twelve months

Rationale

Histoplasmosis treatment is severity-based. Mild-to-moderate pulmonary histoplasmosis is treated with itraconazole 200 mg three times daily for three days as a loading regimen followed by twice-daily dosing for six to twelve weeks. For moderately severe to severe pulmonary disease and for progressive disseminated histoplasmosis — particularly in HIV-positive patients with low CD4 counts — liposomal amphotericin B induction for one to two weeks is required followed by itraconazole step-down therapy for at least twelve months. Secondary prophylaxis with itraconazole is recommended for HIV-positive patients with a history of disseminated disease until the CD4 count exceeds 150 cells per microliter on antiretroviral therapy for at least six months. Fluconazole is less effective than itraconazole for histoplasmosis and is not a standard agent. Voriconazole and echinocandins have no established role in histoplasmosis treatment.

Correct Answer

D — Lifelong fluconazole 400 mg daily; coccidioidal meningitis cannot be cured with currently available antifungal agents, and therapy must continue indefinitely to prevent relapse

Rationale

Coccidioidal meningitis requires lifelong fluconazole suppression at 400 mg daily. This is a defining characteristic of this complication: unlike pulmonary or even disseminated non-meningeal coccidioidomycosis, meningeal disease cannot be cured with any currently available antifungal agent. Discontinuing therapy reliably leads to relapse. Fluconazole is selected for this role because of its excellent central nervous system penetration — cerebrospinal fluid concentrations reach 60 to 80 percent of plasma — and its favorable long-term tolerability profile for indefinite use. Intrathecal amphotericin B was historically used for meningitis refractory to azole therapy but is rarely employed today. Itraconazole is preferred for bone and joint coccidioidomycosis but has poor central nervous system penetration, making it unsuitable for meningeal disease. Twelve-month limited courses are not appropriate for meningeal disease regardless of clinical response.

Correct Answer

B — Blastomycosis disseminates to skin, bone, and genitourinary tract more readily than other endemic fungi even in immunocompetent hosts; severe or central nervous system disease requires liposomal amphotericin B induction followed by itraconazole for twelve months

Rationale

A defining feature of blastomycosis is its tendency to disseminate beyond the lungs — to skin (producing verrucous or ulcerative lesions), bone, and the genitourinary tract — more readily than histoplasmosis or coccidioidomycosis, and even in immunocompetent hosts. This distinguishes it clinically from the other major endemic mycoses where dissemination is more strongly linked to immunocompromise. Treatment follows a severity-based approach: itraconazole for mild-to-moderate pulmonary and non-life-threatening disseminated disease; liposomal amphotericin B induction for moderately severe to severe pulmonary disease, central nervous system involvement, or immunocompromised hosts, followed by itraconazole step-down for twelve months. Blastomycosis is not transmitted person-to-person. Spherule formation in tissue is characteristic of Coccidioides, not Blastomyces. Blastomycosis does cause disease in immunocompetent hosts, and treatment is required for symptomatic disseminated disease regardless of immune status.

Correct Answer

C — An echinocandin is preferred as initial therapy in severely ill patients and those with prior azole exposure, regardless of species or in vitro susceptibility, because of superior fungicidal activity and reduced risk of selecting azole-tolerant populations

Rationale

Current guidelines recommend an echinocandin as the preferred initial therapy for candidemia in most hospitalized patients, and particularly in those who are severely ill or have had prior azole exposure. The reasons include superior fungicidal activity against Candida compared to the fungistatic azoles, and reduced risk of selecting azole-tolerant or resistant subpopulations in patients with prior azole exposure. This recommendation applies regardless of species and regardless of in vitro susceptibility results — even a confirmed fluconazole-susceptible isolate should be treated initially with an echinocandin in a severely ill patient. Step-down to oral fluconazole is appropriate after clinical stabilization, documented negative blood cultures, and confirmed susceptibility. Candida tropicalis is generally fluconazole-susceptible — it does not have intrinsic resistance. Fluconazole does have a role in candidemia, but as step-down therapy rather than empiric initial treatment in high-risk patients.

Correct Answer

C — Deferoxamine acts as a siderophore that delivers iron directly to Mucorales organisms, which require iron for growth and virulence — continuing it actively fuels the infection

Rationale

Deferoxamine must be stopped immediately in any patient with known or suspected mucormycosis because it serves as a xenosiderophore for Mucorales organisms. Mucorales fungi have a ferrioxamine receptor on their surface that allows them to extract iron from the deferoxamine-iron complex, providing them with the iron required for growth, hyphal invasion, and virulence. Rather than removing iron from the infection site as intended, deferoxamine in the setting of mucormycosis delivers iron directly to the pathogen. Deferoxamine use is itself an established risk factor for the development of mucormycosis — patients receiving it are at dramatically increased risk of acquiring this infection. Stopping deferoxamine eliminates this fungal iron supply and removes a major driver of infection progression. The high serum ferritin in this patient reflects transfusional iron overload, and while iron overload management is a legitimate long-term concern, continuing deferoxamine during active mucormycosis is contraindicated. Deferoxamine does not chelate amphotericin B, does not block amphotericin B from accessing fungal ergosterol, and does not compete with amphotericin B for renal transport.

Correct Answer

D — Start liposomal amphotericin B immediately, arrange urgent surgical debridement, and initiate treatment of the diabetic ketoacidosis — all three interventions simultaneously without waiting for mycologic confirmation

Rationale

The clinical presentation — uncontrolled diabetes with ketoacidosis, nasal eschar, periorbital swelling, and proptosis — is characteristic rhinoorbitalcerebral mucormycosis, a rapidly progressive and potentially fatal infection. All three interventions must begin immediately and simultaneously, without waiting for mycologic confirmation. Liposomal amphotericin B at five mg/kg per day is the antifungal of choice. Urgent surgical debridement is essential because Mucorales angioinvasion causes tissue necrosis that limits drug penetration, and antifungal therapy alone cannot sterilize necrotic tissue. Control of diabetic ketoacidosis is equally essential because the high-glucose, acidic environment created by ketoacidosis specifically promotes Mucorales growth and impairs host immune defenses. Voriconazole has no Mucorales activity and must not be used. Deferring surgery pending antifungal effect dramatically worsens outcomes. Fluconazole has no mold activity.

Correct Answer

B — Liposomal amphotericin B induction for one to two weeks followed by itraconazole step-down for at least twelve months, with secondary prophylaxis continued until the CD4 count exceeds 150 cells per microliter on antiretroviral therapy for at least six months

Rationale

This patient has progressive disseminated histoplasmosis in the setting of advanced HIV infection with a CD4 count well below 150 cells per microliter — the category that requires liposomal amphotericin B induction rather than oral itraconazole alone. The clinical features — fever, weight loss, hepatosplenomegaly, and strongly positive urine antigen — confirm moderately severe to severe disseminated disease. Treatment consists of liposomal amphotericin B at three to five mg/kg per day for one to two weeks as induction, followed by step-down to itraconazole for at least twelve months. Secondary prophylaxis with itraconazole 200 mg daily is then continued until the CD4 count has exceeded 150 cells per microliter on effective antiretroviral therapy for at least six months. Itraconazole alone without amphotericin B induction is reserved for mild-to-moderate disease. Voriconazole has no established efficacy for histoplasmosis. Fluconazole has activity against Histoplasma but is less effective than itraconazole and is not the preferred agent for disseminated disease.